WO2001054688A1 - Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug - Google Patents
Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug Download PDFInfo
- Publication number
- WO2001054688A1 WO2001054688A1 PCT/US2001/002405 US0102405W WO0154688A1 WO 2001054688 A1 WO2001054688 A1 WO 2001054688A1 US 0102405 W US0102405 W US 0102405W WO 0154688 A1 WO0154688 A1 WO 0154688A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cox
- prostate cancer
- accordance
- hydrochloride
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002396593A CA2396593A1 (en) | 2000-01-28 | 2001-01-25 | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
EP01908690A EP1253921A4 (en) | 2000-01-28 | 2001-01-25 | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
AU36533/01A AU3653301A (en) | 2000-01-28 | 2001-01-25 | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17872200P | 2000-01-28 | 2000-01-28 | |
US60/178,722 | 2000-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001054688A1 true WO2001054688A1 (en) | 2001-08-02 |
Family
ID=22653676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/002405 WO2001054688A1 (en) | 2000-01-28 | 2001-01-25 | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
Country Status (5)
Country | Link |
---|---|
US (1) | US6486204B2 (en) |
EP (1) | EP1253921A4 (en) |
AU (1) | AU3653301A (en) |
CA (1) | CA2396593A1 (en) |
WO (1) | WO2001054688A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035081A1 (en) * | 2001-10-19 | 2003-05-01 | Novartis Ag | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
US6825185B2 (en) | 2000-12-21 | 2004-11-30 | Nitromed, Inc. | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
WO2006002488A1 (en) * | 2004-07-06 | 2006-01-12 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
WO2007109852A1 (en) * | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Selenium for treatment of cancer |
WO2007109853A1 (en) * | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Inorganic selenium for treatment of benign tumors |
EP2018853A1 (en) | 2000-01-26 | 2009-01-28 | AstraZeneca AB | Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092565A1 (en) * | 2001-07-25 | 2004-05-13 | George Kindness | Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin |
MXPA05004503A (en) * | 2002-10-31 | 2005-08-16 | Metabasis Therapeutics Inc | Novel cytarabine monophosphate prodrugs. |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
EP1663103B1 (en) * | 2003-09-08 | 2011-11-09 | Genyous Biomed International Inc. | Compositions of botanical extracts for cancer therapy |
CA2600276C (en) * | 2005-03-08 | 2013-01-08 | Mitsui Norin Co., Ltd | Polyphenol coxib combinations and methods |
US7597910B2 (en) * | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
WO2007047553A2 (en) * | 2005-10-14 | 2007-04-26 | Zweig Jack I | Methods and compositions for treatment of prostate intraepithelial neoplasia |
CZ300590B6 (en) * | 2006-06-20 | 2009-06-24 | Pliva - Lachema A. S. | Pharmaceutical composition for administration by injection |
US20080025972A1 (en) * | 2006-07-26 | 2008-01-31 | Duke University | Treating sex steriod responsive disorders |
JP2017512183A (en) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Prodrug compounds and their use |
CN106687118A (en) | 2014-07-02 | 2017-05-17 | 配体药物公司 | Prodrug compounds and uses thereof |
US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020343A (en) * | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
UA57002C2 (en) * | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment |
FR2751649B1 (en) | 1996-07-26 | 1998-08-28 | Adir | NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
PT1479385E (en) * | 1996-10-15 | 2008-09-02 | Searle Llc | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
ATE250576T1 (en) | 1996-12-10 | 2003-10-15 | Searle & Co | SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION |
JP4733266B2 (en) * | 1997-12-19 | 2011-07-27 | ニューヨーク ユニバーシティ | Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha |
US6326507B1 (en) * | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
EP1150973B1 (en) * | 1999-02-11 | 2005-06-15 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
EP1259237A4 (en) * | 2000-02-17 | 2004-07-28 | Merck & Co Inc | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
JP2004517838A (en) * | 2000-12-15 | 2004-06-17 | ファルマシア・コーポレーション | Selective COX-2 inhibition by non-edible plant extracts |
-
2001
- 2001-01-25 EP EP01908690A patent/EP1253921A4/en not_active Withdrawn
- 2001-01-25 AU AU36533/01A patent/AU3653301A/en not_active Abandoned
- 2001-01-25 WO PCT/US2001/002405 patent/WO2001054688A1/en not_active Application Discontinuation
- 2001-01-25 CA CA002396593A patent/CA2396593A1/en not_active Abandoned
- 2001-01-26 US US09/771,315 patent/US6486204B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
LIU ET AL.: "Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line", CLINICAL AND EXPERIMENTAL METASTASIS, vol. 17, no. 8, 1999, pages 687 - 694, XP002941003 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2018853A1 (en) | 2000-01-26 | 2009-01-28 | AstraZeneca AB | Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
US6825185B2 (en) | 2000-12-21 | 2004-11-30 | Nitromed, Inc. | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
WO2003035081A1 (en) * | 2001-10-19 | 2003-05-01 | Novartis Ag | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
AU2002363089B2 (en) * | 2001-10-19 | 2006-02-16 | Novartis Ag | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol |
CN100372539C (en) * | 2001-10-19 | 2008-03-05 | 诺瓦提斯公司 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
US7345088B2 (en) | 2001-10-19 | 2008-03-18 | Penn State Research Foundation | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
WO2006002488A1 (en) * | 2004-07-06 | 2006-01-12 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
WO2007109852A1 (en) * | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Selenium for treatment of cancer |
WO2007109853A1 (en) * | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Inorganic selenium for treatment of benign tumors |
Also Published As
Publication number | Publication date |
---|---|
EP1253921A1 (en) | 2002-11-06 |
AU3653301A (en) | 2001-08-07 |
EP1253921A4 (en) | 2004-10-13 |
CA2396593A1 (en) | 2001-08-02 |
US20010047022A1 (en) | 2001-11-29 |
US6486204B2 (en) | 2002-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20010041713A1 (en) | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug | |
US6486204B2 (en) | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug | |
Hande | Clinical applications of anticancer drugs targeted to topoisomerase II | |
US7326734B2 (en) | Treatment of bladder and urinary tract cancers | |
AU2003286647B2 (en) | Method and composition for preventing and treating solid tumors | |
US5773419A (en) | Method of treating cancer with tannic acid | |
EP2127652A1 (en) | Method for treating cancer using anticancer agent in combination | |
EA006294B1 (en) | Use a celecoxib and gemcitabine combination in a combined method for treating pancreas | |
WO1994009772A1 (en) | Dithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases | |
US20080113951A1 (en) | Treatment of inflammatory, cancer, and thrombosis disorders | |
WO2021263250A2 (en) | Method of treating severe forms of pulmonary hypertension | |
JP2005508857A (en) | Drug combinations for treating neoplastic diseases | |
JP2006503872A (en) | Extracts with antitumor and antitoxic activity | |
Mehta et al. | Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation | |
US9907852B2 (en) | Anticancer agent and side-effect-alleviating agent | |
US20200375943A1 (en) | Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect | |
JP2006527232A (en) | Pharmaceutical combination preparation for cancer treatment containing glutaminase and antineoplastic anthracyclines or platinum compounds | |
EP3955947A1 (en) | Method and composition for reversing and/or inhibiting atherosclerosis | |
DE10016771C2 (en) | Use of flavones or flavonols to prevent bowel diseases | |
Lockwood | Leukemia: AML, CML, ALL and CLL | |
KR20220121532A (en) | Colon disease pharmaceutical composition and its Treatment | |
CA2655614A1 (en) | Treatment of cancer with 2-deoxygalactose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2396593 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 36533/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001908690 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001908690 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001908690 Country of ref document: EP |